What is Retension Pharmaceuticals, Inc. Common Stock?
operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 102.23M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.